PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: €35.00 through €91.50
GHRP-2 EU – Buy Online | In Stock & Ready to Ship
Buy GHRP-2 in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for GHRP-2 Europe suppliers, looking to buy GHRP-2 in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide ghrelin mimetic and one of the most potent GHS-R1a agonists available, offered for sale in Europe for laboratory research into growth hormone secretion, ghrelin receptor pharmacology, pituitary biology, and metabolic signalling.
Laboratories and research institutions across the EU can order verified, research-grade GHRP-2 with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA)
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch to EU & Europe | Tracked Shipping
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide — sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2 — and a second-generation member of the growth hormone secretagogue (GHS) peptide class. Like GHRP-6 before it, GHRP-2 acts as a ghrelin mimetic at the GHS-R1a receptor to stimulate pituitary growth hormone release — but with greater potency per unit dose and a receptor engagement profile that has made it one of the most widely used GHS compounds in endocrine research.
GHRP-2 was developed as a refined successor to GHRP-6 with the aim of improving GH secretagogue potency while retaining the well-characterised GHS-R1a mechanism. Studies comparing the two compounds have consistently documented GHRP-2’s superior GH-stimulating efficacy, alongside a higher co-stimulation of cortisol and prolactin that distinguishes its receptor activity profile from more selective later-generation compounds such as Ipamorelin.
Its potency, well-established pharmacology, and extensive comparative research literature make GHRP-2 a central reference compound for studying GHS-R1a receptor biology, pituitary somatotroph function, and the broader neuroendocrine regulation of growth hormone secretion in pre-clinical research settings across Europe and the EU.
In laboratory settings, GHRP-2 is studied primarily as a high-potency GHS-R1a agonist and growth hormone secretagogue, with research extending into pituitary biology, neuroendocrine regulation, and metabolic signalling. EU and European researchers working with GHRP-2 typically focus on:
All research applications are for in vitro and pre-clinical use only.
GHRP-2 has an extensive and well-characterised research literature spanning endocrinology, receptor pharmacology, metabolic biology, and neuroendocrine regulation — with decades of pre-clinical and clinical investigation establishing it as one of the most studied synthetic growth hormone secretagogues.
GH secretagogue potency: Studies have consistently documented GHRP-2 as producing greater GH release per unit dose than GHRP-6 in direct comparisons, with robust dose-dependent GH secretion characterised across multiple pre-clinical and clinical research models. Its potency has made it the preferred GHS compound in studies requiring maximal pituitary GH stimulation.
GHS-R1a receptor pharmacology: Research has characterised GHRP-2’s binding kinetics and activation profile at GHS-R1a in detail, contributing to the broader understanding of ghrelin receptor pharmacology developed through study of the synthetic GHS peptide class. GHRP-2 has been used extensively in competitive binding assays and receptor mutagenesis studies examining GHS-R1a binding pocket geometry.
Cortisol and prolactin co-stimulation: A well-documented feature of GHRP-2’s pharmacology is its stronger co-stimulation of ACTH/cortisol and prolactin release compared to GHRP-6 — and substantially more than Ipamorelin. Studies have characterised this as reflecting broader hypothalamic and pituitary receptor engagement beyond pure GHS-R1a selectivity, making GHRP-2 a useful tool for examining the full scope of GHS effects on pituitary hormone secretion.
Synergy with GHRH: Research has consistently shown that GHRP-2 combined with GHRH produces substantially greater GH release than either compound alone — a synergistic interaction reflecting complementary mechanisms at the pituitary somatotroph. This synergy has been characterised in both animal models and human clinical research, with the GHRP-2 plus GHRH combination used as a diagnostic tool in pituitary function assessment studies.
IGF-1 and metabolic effects: Studies examining GHRP-2 in the context of GH axis modulation have documented downstream effects on IGF-1 production, lean mass parameters, and lipid metabolism in pre-clinical models — findings that have positioned GHRP-2 as a research tool for metabolic biology beyond its direct receptor pharmacology application.
Neuroendocrine regulation: Research has characterised GHRP-2 effects on hypothalamic somatostatin release — the primary inhibitory regulator of pituitary GH secretion — with findings suggesting GHS-R1a activation suppresses somatostatin tone as part of the mechanism driving enhanced GH release. This line of investigation has contributed to the understanding of how GHS compounds modulate the full neuroendocrine GH regulatory circuit.
| Compound | Type | GH Potency | Cortisol/Prolactin Effect | Key Research Distinction |
|---|---|---|---|---|
| GHRP-2 | Hexapeptide GHS | Very High | Higher | Maximum GH potency reference compound, HPA co-stimulation research |
| GHRP-6 | Hexapeptide GHS | High | Moderate | Orexigenic effects, cardioprotection research, longer established literature |
| Ipamorelin | Pentapeptide GHS | Moderate–High | Minimal | High GHS-R1a selectivity, cleanest GH-specific research tool |
| Hexarelin | Hexapeptide GHS | Very High | Higher | Cardioprotection via CD36, comparable potency to GHRP-2 |
| MK-677 (Ibutamoren) | Non-peptide GHS | High | Moderate | Oral bioavailability, long half-life, extended metabolic research |
| CJC-1295 | GHRH analogue | High (via GHRH-R) | Minimal | Synergistic partner for GHS compounds, extended half-life GHRH activity |
Every order of GHRP-2 peptide dispatched to EU and European research institutions includes:
Yes. We supply research-grade GHRP-2 peptide with fast tracked international dispatch to all EU member states and wider European destinations. Packaging is designed to maintain peptide integrity throughout transit, and all orders include full batch documentation. GHRP-2 is supplied strictly for laboratory research use only.
GHRP-2 and GHRP-6 are both hexapeptide GHS-R1a agonists with closely related mechanisms, but GHRP-2 produces greater GH release per unit dose and higher co-stimulation of cortisol and prolactin. GHRP-6 is more orexigenic — producing stronger appetite-stimulating effects through hypothalamic pathways — and has a longer established research literature including a distinct cardioprotection research base. In practice, GHRP-2 is preferred when maximal GH secretagogue potency is the research priority, while GHRP-6 is favoured for appetite biology and broader ghrelin pathway research.
Ipamorelin is a later-generation pentapeptide GHS designed specifically for improved GHS-R1a selectivity and minimal off-target receptor activity. Compared to GHRP-2, Ipamorelin produces little to no co-stimulation of cortisol or prolactin — making it the cleaner tool for research focused exclusively on GH axis effects. GHRP-2’s higher potency and broader receptor activity profile make it more useful for research examining the full scope of GHS-R1a pharmacology, including HPA axis interactions and comparative potency studies.
GHRP-2’s co-stimulation of cortisol and prolactin reflects GHS-R1a receptor expression at hypothalamic and pituitary sites beyond the somatotroph cells responsible for GH release. GHS-R1a activation in the hypothalamus influences CRH and other regulatory peptide release, while pituitary GHS-R1a expression on corticotroph and lactotroph cells contributes to ACTH/cortisol and prolactin secretion respectively. This broader activity profile is well-characterised in the literature and is a key variable in comparative GHS pharmacology research — distinguishing GHRP-2 from more selective compounds like Ipamorelin.
Yes — this is one of GHRP-2’s most well-documented and research-relevant properties. Studies combining GHRP-2 with GHRH or long-acting GHRH analogues such as CJC-1295 have consistently shown substantially greater GH release than either compound produces alone, due to their complementary mechanisms at the pituitary somatotroph. The GHRP-2 plus GHRH combination has been studied in both pre-clinical and clinical research settings and has been used as a diagnostic tool in pituitary function assessment.
Allow the vial to reach room temperature before opening. Add sterile water or an appropriate laboratory buffer slowly down the vial wall and swirl gently — do not shake. Prepare at your protocol’s required concentration, aliquot, and store at -80°C to minimise freeze-thaw degradation. Standard peptide handling protocols apply.
Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to protect peptide stability throughout transit.
| Parameter | Detail |
|---|---|
| Sequence | D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2 |
| Type | Synthetic Hexapeptide Growth Hormone Secretagogue |
| Receptor Target | GHS-R1a (Ghrelin Receptor) |
| Primary Research Interest | High-potency GH secretagogue, ghrelin receptor pharmacology, neuroendocrine regulation |
| Purity | ≥99% |
| Verification | HPLC & Mass Spectrometry |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water or laboratory buffer |
| Storage | -20°C, protected from light and moisture |
| Intended Use | Research use only |
GHRP-2 is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.
Receive News
